Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer

Robert Vince, Jay Brownell

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

(+/-) Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir; NSC 614846) is an antiretroviral agent which is undergoing preclinical evaluation for the treatment of AIDS. Racemic carbovir was separated into its D and L enantiomers by the action of adenosine deaminase on the 2,6-diaminopurine precursor. Subsequent evaluation of the enantiomers against human immunodeficiency virus type 1 revealed that the antiviral activity of carbovir resides in the (-) isomer that is analagous to the nucleoside, β-D-2′,3′-didehydro-2′,3′-dideoxyguanosine.

Original languageEnglish (US)
Pages (from-to)912-916
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume168
Issue number3
DOIs
StatePublished - May 16 1990

Fingerprint Dive into the research topics of 'Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer'. Together they form a unique fingerprint.

Cite this